STOCK TITAN

Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Marker Therapeutics (MRKR) was awarded a $16.2 million grant from the Cancer Prevention and Research Institute of Texas. The non-dilutive funding will support the planned Phase 2 APOLLO study of MT-601 (neldaleucel), an investigational cell therapy for patients with relapsed or refractory large B-cell lymphoma after CD19-directed CAR-T therapy.

In August 2025, Marker reported a 66% objective response rate and a 50% complete response rate among 12 evaluable Phase 1 patients with non-Hodgkin lymphoma. Responses lasted up to 24 months at the data cutoff. No dose-limiting toxicities or immune effector cell-associated neurotoxicity syndrome were observed across the dose levels evaluated. Marker expects additional patient data and updated data on how long responses lasted later in 2026.

Loading...
Loading translation...
6 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point. Forward-looking: it has not happened yet and may not happen.$16.2 million non-dilutive grant from the Cancer Prevention and Research Institute of Texas supports the planned Phase 2 APOLLO study of MT-601 1.1× market cap
  • Minor pointPhase 1 objective response rate was 66% among 12 evaluable patients with non-Hodgkin lymphoma
  • Minor pointPhase 1 complete response rate was 50% among 12 evaluable patients with non-Hodgkin lymphoma
  • Minor pointPhase 1 responses lasted up to 24 months at the data cutoff
  • Minor pointPhase 1 safety findings showed no dose-limiting toxicities or immune effector cell-associated neurotoxicity syndrome across evaluated doses
  • Minor point. Forward-looking: it has not happened yet and may not happen.Additional patient data and updated response-duration data are expected later in 2026

Negative

  • None.

Key Figures

CPRIT grant: $16.2 million Objective response rate: 66% Complete response rate: 50% +1 more
CPRIT grant
$16.2 million
Awarded to support planned Phase 2 APOLLO development
Objective response rate
66%
Phase 1; 12 evaluable patients with non-Hodgkin lymphoma
Complete response rate
50%
Phase 1; 12 evaluable patients with non-Hodgkin lymphoma
Response duration
Up to 24 months
Phase 1 responses at the time of data cutoff

Previous Clinical trial Reports

1 past event · Latest: Aug 26
Same Type 1 event
  1. Aug 26

    Phase 1 data

    24h Move
    -20.6%

    APOLLO Phase 1 reported 66% objective responses and 50% complete responses in NHL.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

car-t, objective response rate, dose-limiting toxicities, immune-effector cell-associated neurotoxicity syndrome
4 terms
car-t medical
"patients who had previously received CAR-T cells"
CAR-T is a type of cancer therapy that reprograms a patient’s own immune cells to seek and destroy specific cancer cells, like teaching guard dogs a new scent to track intruders. It matters to investors because CAR-T treatments can command high prices, drive strong revenue for successful developers, and carry regulatory and manufacturing risks that can sharply affect a company’s valuation and long-term growth prospects.
objective response rate medical
"a 66% objective response rate"
The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.
dose-limiting toxicities medical
"with no dose-limiting toxicities"
Dose-limiting toxicities are the harmful side effects seen in early clinical trials that are severe enough to stop researchers from raising a drug’s dose. Like a car’s speed limiter marking the safe top speed, DLTs define the maximum tolerable dose, and they matter to investors because they determine whether a medicine can reach effective levels, influence development timelines, costs, and regulatory chances, and thus affect a drug’s commercial prospects.
immune-effector cell-associated neurotoxicity syndrome medical
"immune-effector cell-associated neurotoxicity syndrome (ICANS)"
An immune-effector cell-associated neurotoxicity syndrome (ICANS) is a brain-related side effect that can occur after treatments that unleash the immune system against disease, such as engineered cell therapies; it can cause confusion, trouble speaking, seizures or loss of consciousness. Investors care because ICANS affects a therapy’s safety profile, regulatory review, patient access and potential costs — like a product recall or warranty issue that can slow sales, raise liabilities and influence a drug’s market value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Highly competitive grant award provides significant non-dilutive funding to support Phase 2 development of MT-601 in CAR-relapsed lymphoma

CPRIT award builds on encouraging Phase 1 clinical results, with additional patient data and updated response durability data expected later this year

Independent scientific, clinical, and commercial review reinforces the potential of MT-601 in relapsed large B-cell lymphoma

HOUSTON, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies under an exclusive worldwide license from Baylor College of Medicine for patients with cancer. Today, Marker announced that the Company has been awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The funding will support the advancement of the Company’s lead investigational MAR-T cell therapy, MT-601 (neldaleucel), in the planned Phase 2 APOLLO study for patients with relapsed or refractory large B-cell lymphoma (LBCL) following treatment with CD19-directed chimeric antigen receptor (CAR)-T cells.

The CPRIT Product Development Research program is a highly competitive funding initiative established by the State of Texas to advance innovative cancer therapies toward commercialization. Applications undergo a rigorous multistage evaluation involving independent scientific and industry experts, including assessment of scientific merit, clinical development strategy, regulatory considerations, intellectual property, manufacturing feasibility, and commercial potential. For this funding cycle, CPRIT received 207 applications and awarded a total of $74.3 million to 12 projects.

“Securing this $16.2 million award from CPRIT is an important milestone for Marker and further reinforces our confidence in the potential of MT-601 in CAR-relapsed lymphoma,” said Juan Vera, MD, President and Chief Executive Officer of Marker Therapeutics. “Following a highly competitive selection and review process, this award provides meaningful external recognition of our differentiated MAR-T cell approach and substantial non-dilutive funding to support our Phase 2 APOLLO study to translate our early clinical findings into a much-needed new treatment option for patients with limited therapeutic alternatives. We look forward to providing updated clinical results later this year and advancing MT-601 through its next stage of clinical development.”

The CPRIT award builds on encouraging clinical results from the Phase 1 APOLLO study (clinicaltrials.gov identifier: NCT05798897) evaluating MT-601 in patients with heavily pretreated lymphoma, including patients who had previously received CAR-T cells and bispecific antibodies. In August 2025, Marker reported a 66% objective response rate and a 50% complete response rate among 12 evaluable patients with non-Hodgkin lymphoma. Durable responses were observed, including responses lasting up to 24 months at the time of the data cutoff (Press Release, August 26, 2025). MT-601 also demonstrated a favorable safety profile across evaluated dose levels, with no dose-limiting toxicities or immune-effector cell-associated neurotoxicity syndrome (ICANS).

“Despite significant advances in the treatment of large B-cell lymphoma, patients who relapse following CAR-T therapy continue to face limited treatment options and poor clinical outcomes,” commented Geoffrey Shouse, D.O., Ph.D., Principal Investigator at City of Hope National Medical Center in Duarte, California. “Through our experience with MT-601 in the Phase 1 APOLLO study, we have observed encouraging clinical activity and a favorable safety profile in heavily pretreated patients, including those who have progressed following multiple prior lines of therapy. We believe MT-601 represents a promising therapeutic approach and has the potential to meaningfully change the treatment landscape for patients with LBCL who relapse after CAR-T therapy.”

The CPRIT award further strengthens Marker’s track record of securing competitive federal and state funding to support the Company’s innovative MAR-T cell platform. The award builds on previously secured non-dilutive funding from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program to support the Phase 1 clinical development of MT-601 in CAR-relapsed lymphoma.

“The awards funded reflect the extraordinary innovation taking place across Texas," said CPRIT Chief Executive Officer Kristen Doyle, commenting on CPRIT’s latest funding awards. "These investments support researchers, clinicians, entrepreneurs, and community leaders who are helping shape the future of cancer care and bringing new hope to Texans and Texas families.”

About the Cancer Prevention and Research Institute of Texas (CPRIT)
Created by the Texas Legislature and approved by Texas voters in 2007, the Cancer Prevention and Research Institute of Texas (CPRIT) is the state's premier agency for advancing cancer research, prevention, and innovation. In 2019, Texans overwhelmingly reaffirmed their commitment to CPRIT by approving an additional $3 billion in funding, bringing the state's total investment to $6 billion.

Since its inception, CPRIT has awarded more than $4 billion in grants to Texas research institutions and organizations through its academic research, prevention, and product development programs. CPRIT-funded investments have helped recruit 370 distinguished researchers to Texas, supported the establishment, expansion, or relocation of 90 companies, and delivered 13 million cancer prevention services across all 254 Texas counties.

About MT-601
The Company’s lead product, MT-601 (neldaleucel), is a multi-antigen recognizing (MAR) T cell product that utilizes a non-genetically modified approach that specifically targets six different tumor antigens upregulated in lymphoma cells (Survivin, PRAME, WT-1, NY-ESO-1, SSX-2, MAGEA-4). Marker is currently investigating MT-601 in the Company-sponsored Phase 1 APOLLO trial (clinicaltrials.gov identifier: NCT05798897) for the treatment of patients with lymphoma who have relapsed after or are not candidates for anti-CD19 CAR-T cell therapies.

About APOLLO
The APOLLO trial (clinicaltrials.gov Identifier: NCT05798897) is a Phase 1, multicenter, open-label study designed to evaluate the safety and efficacy of MT-601 (neldaleucel) in participants with relapsed or refractory lymphoma who have either failed anti-CD19 chimeric antigen receptor (CAR) T cell therapy or are not candidates for anti-CD19 CAR-T cell therapy. The primary objective of this exploratory Phase 1 clinical trial is to evaluate the optimum dose, safety, and preliminary efficacy of MT-601 in participants with various lymphoma subtypes. The APOLLO study is supported by competitive federal and state research grants, including from the Cancer Prevention and Research Institute of Texas (CPRIT) and the National Cancer Institute of the National Institutes of Health (Award Number R44CA291521).

About MAR-T cells
The multi-antigen recognizing (MAR) T cell platform (formerly known as multiTAA-specific T cells) is a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient's/donor’s blood capable of recognizing a broad range of tumor antigens. Unlike other T cell therapies, MAR-T cells allow the recognition of hundreds of different epitopes within up to six tumor-specific antigens, thereby reducing the possibility of tumor escape. Since MAR-T cells are not genetically engineered, Marker believes that its product candidates will be easier and less expensive to manufacture, with an improved safety profile compared to current engineered T cell approaches and may provide patients with meaningful clinical benefits.

About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company was founded at Baylor College of Medicine, and clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company’s autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. Marker’s goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker’s unique T cell platform is strengthened by non-dilutive funding from U.S. state and federal agencies supporting cancer research, including the National Cancer Institute of National Institutes of Health, U.S. Department of War, the FDA Orphan Drug program and the Cancer Prevention Research Institute of Texas (CPRIT).

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.

Forward-Looking Statements
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and the timing, conduct, interim results announcements and outcomes of our clinical trials of our product candidates, including neldaleucel (MT-601) for the treatment of patients with pancreatic cancer or lymphoma. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at WWW.SEC.GOV. The Company assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release except as may be required by law.

Media and Investor Contact

Marker Therapeutics, Inc.
+1 (713) 400-6400
investor.relations@markertherapeutics.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much funding did Marker Therapeutics receive for the Phase 2 APOLLO study?

Marker Therapeutics was awarded $16.2 million in non-dilutive funding from the Cancer Prevention and Research Institute of Texas. The grant supports the planned Phase 2 study of MT-601 in patients with relapsed or refractory large B-cell lymphoma after CD19-directed CAR-T therapy.

What did Marker Therapeutics report from the Phase 1 APOLLO study of MT-601?

Marker reported a 66% objective response rate and a 50% complete response rate among 12 evaluable patients with non-Hodgkin lymphoma. Responses lasted up to 24 months at the data cutoff.

How was Marker Therapeutics' MT-601 application reviewed for the Texas cancer research grant?

The grant program used a multistage review by independent scientific and industry experts. The review covered scientific merit, clinical development plans, regulatory considerations, intellectual property, manufacturing feasibility and commercial potential. In that funding cycle, the program received 207 applications and awarded a total of $74.3 million to 12 projects.

What funding did Marker Therapeutics secure for MT-601 before the Phase 2 APOLLO award?

Marker previously secured non-dilutive funding from the National Institutes of Health through its Small Business Innovation Research program. That funding supported Phase 1 development of MT-601 in lymphoma that relapsed after CAR-T therapy.

Keep reading